

Dimitrios Vassilopoulos

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8276686/publications.pdf>

Version: 2024-02-01

152
papers

4,333
citations

159585

30
h-index

123424

61
g-index

154
all docs

154
docs citations

154
times ranked

6932
citing authors

#	ARTICLE	IF	CITATIONS
1	An international audit of the management of dyslipidaemia and hypertension in patients with rheumatoid arthritis: results from 19 countries. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2022, 8, 539-548.	3.0	8
2	COVID-19 vaccine safety and nocebo-prone associated hesitancy in patients with systemic rheumatic diseases: a cross-sectional study. <i>Rheumatology International</i> , 2022, 42, 31-39.	3.0	28
3	Better outcomes of COVID-19 in vaccinated compared to unvaccinated patients with systemic rheumatic diseases. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 1013-1016.	0.9	43
4	The effects of golimumab on patient centric outcomes amongst rheumatoid arthritis patients in Greece. The GO-Q study. <i>Rheumatology International</i> , 2022, 42, 639-650.	3.0	0
5	Real-Life Effectiveness and Safety of Baricitinib as Adjunctive to Standard-of-Care Treatment in Hospitalized Patients With Severe Coronavirus Disease 2019. <i>Open Forum Infectious Diseases</i> , 2022, 9, ofab588.	0.9	7
6	Patient characteristics, treatment patterns and disease outcomes in patients with psoriatic arthritis followed in a combined Dermatology&Rheumatology clinic: a retrospective real-world study. <i>Rheumatology International</i> , 2022, , 1.	3.0	1
7	A case of adenoviral covid-19 vector vaccine possibly linked to severe but reversible interstitial lung injury post-vaccination. <i>Infectious Diseases</i> , 2022, 54, 692-697.	2.8	2
8	Oral antiviral treatment in patients with systemic rheumatic disease at risk for development of severe COVID-19: a case series. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 1477-1479.	0.9	9
9	Editorial commentary: Recurrent pericarditis in the era of interleukin-1 inhibition. <i>Trends in Cardiovascular Medicine</i> , 2021, 31, 275-276.	4.9	11
10	Comparable or higher prevalence of comorbidities in antiphospholipid syndrome <i>vs</i> rheumatoid arthritis: a multicenter, case-control study. <i>Rheumatology</i> , 2021, 60, 170-178.	1.9	24
11	2019 EULAR points to consider for the assessment of competences in rheumatology specialty training. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 65-70.	0.9	12
12	Hypogammaglobulinemia after rituximab for rheumatoid arthritis is not rare and is related with good response: 13 years real-life experience. <i>Rheumatology</i> , 2021, 60, 2375-2382.	1.9	19
13	Outcome of refractory to conventional and/or biologic treatment adult Still's disease following canakinumab treatment: Countrywide data in 50 patients. <i>Seminars in Arthritis and Rheumatism</i> , 2021, 51, 137-143.	3.4	22
14	Incidence, risk factors and validation of the RABBIT score for serious infections in a cohort of 1557 patients with rheumatoid arthritis. <i>Rheumatology</i> , 2021, 60, 2223-2230.	1.9	8
15	Age&sex-based differences in patients with acute pericarditis. <i>European Journal of Clinical Investigation</i> , 2021, 51, e13392.	3.4	16
16	Increased influenza vaccination rates in patients with autoimmune rheumatic diseases during the Covid-19 pandemic: a cross-sectional study. <i>Rheumatology International</i> , 2021, 41, 895-902.	3.0	15
17	Serious infections in ANCA-associated vasculitides in the biologic era: real-life data from a multicenter cohort of 162 patients. <i>Arthritis Research and Therapy</i> , 2021, 23, 90.	3.5	6
18	Associations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis: Results from the COVID-19 Global Rheumatology Alliance physician registry. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 1137-1146.	0.9	151

#	ARTICLE	IF	CITATIONS
19	A risk score for pericarditis recurrence. <i>European Journal of Clinical Investigation</i> , 2021, 51, e13602.	3.4	11
20	Diabetes mellitus and cardiovascular risk management in patients with rheumatoid arthritis: an international audit. <i>RMD Open</i> , 2021, 7, e001724.	3.8	12
21	Kinetics of quantitative hepatitis B surface antigen in patients with rheumatic disease and chronic hepatitis B receiving biologic agents. <i>Journal of Viral Hepatitis</i> , 2021, 28, 1710-1718.	2.0	1
22	Transforming Growth Factor- β 1/Smad Signaling in Glomerulonephritis and Its Association with Progression to Chronic Kidney Disease. <i>American Journal of Nephrology</i> , 2021, 52, 653-665.	3.1	6
23	A case series of acute pericarditis following COVID-19 vaccination in the context of recent reports from Europe and the United States. <i>Vaccine</i> , 2021, 39, 6585-6590.	3.8	26
24	Editorial: Infection-Related Rheumatic Diseases. <i>Frontiers in Medicine</i> , 2021, 8, 779773.	2.6	0
25	Distal renal tubular acidosis and nephrocalcinosis as initial manifestation of primary Sjögren's syndrome.. <i>Saudi Journal of Kidney Diseases and Transplantation: an Official Publication of the Saudi Center for Organ Transplantation, Saudi Arabia</i> , 2021, 32, 1470-1474.	0.3	1
26	Anakinra for corticosteroid-dependent and colchicine-resistant pericarditis: The IRAP (International Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 956-964.	1.8	98
27	Introduction and switching of biologic agents are associated with antidepressant and anxiolytic medication use: data on 42 815 real-world patients with inflammatory rheumatic disease. <i>RMD Open</i> , 2020, 6, e001303.	3.8	8
28	Treatment patterns and achievement of the treat-to-target goals in a real-life rheumatoid arthritis patient cohort: data from 1317 patients. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2020, 12, 1759720X2093713.	2.7	10
29	Hypocomplementemia is associated with more severe renal disease and worse renal outcomes in patients with ANCA-associated vasculitis: a retrospective cohort study. <i>Renal Failure</i> , 2020, 42, 845-852.	2.1	9
30	Correlation of patient preferences to treatment outcomes in patients with rheumatoid arthritis treated with tumour necrosis factor inhibitors in Greece. <i>Clinical Rheumatology</i> , 2020, 39, 3643-3652.	2.2	8
31	Reactivation of hepatitis B virus infection in rheumatic diseases: risk and management considerations. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2020, 12, 1759720X2091264.	2.7	33
32	Treatment modalities and drug survival in a systemic sclerosis real-life patient cohort. <i>Arthritis Research and Therapy</i> , 2020, 22, 56.	3.5	12
33	Real Life Efficacy and Safety of Secukinumab in Biologic-Experienced Patients With Psoriatic Arthritis. <i>Frontiers in Medicine</i> , 2020, 7, 288.	2.6	12
34	Systemic autoimmune diseases, anti-rheumatic therapies, COVID-19 infection risk and patient outcomes. <i>Rheumatology International</i> , 2020, 40, 1353-1360.	3.0	33
35	Hydroxychloroquine for colchicine-resistant glucocorticoid-dependent idiopathic recurrent pericarditis: A pilot observational prospective study. <i>International Journal of Cardiology</i> , 2020, 311, 77-82.	1.7	20
36	Conversion and Reversion Rates of Tuberculosis Screening Assays in Patients With Rheumatic Diseases and Negative Baseline Screening Under Long-Term Biologic Treatment. <i>Pathogens and Immunity</i> , 2020, 5, 34.	3.1	9

#	ARTICLE	IF	CITATIONS
37	Infections in Patients with Rheumatoid Arthritis in the Era of Targeted Synthetic Therapies. Mediterranean Journal of Rheumatology, 2020, 31, 129.	0.8	16
38	Patients'™ and Doctors'™ Beliefs about Treatment and Long-Term Adherence in Rheumatic Diseases. Mediterranean Journal of Rheumatology, 2020, 31, 152.	0.8	5
39	Mitophagy Balance in Various Cell Subsets in Patients with ANCA-Associated Vasculitis and Correlation with the Presence of Anti-Neutrophil Cytoplasmic Antibodies. Mediterranean Journal of Rheumatology, 2020, 31, 366.	0.8	0
40	Updated Greek Rheumatology Society Guidelines for the Management of Rheumatoid Arthritis. Mediterranean Journal of Rheumatology, 2020, 31, 163.	0.8	1
41	Management of Patients with Inflammatory Diseases during the COVID-19 Pandemic. Mediterranean Journal of Rheumatology, 2020, 31, 295.	0.8	1
42	The landscape of acute pericarditis in Greece: Experience from a tertiary referral center. Hellenic Journal of Cardiology, 2019, 60, 139-140.	1.0	12
43	An emerging role of neutrophils and NETosis in chronic inflammation and fibrosis in systemic lupus erythematosus (SLE) and ANCA-associated vasculitides (AAV): Implications for the pathogenesis and treatment. Autoimmunity Reviews, 2019, 18, 751-760.	5.8	115
44	Clinical significance of pleural effusions and association with outcome in patients hospitalized with a first episode of acute pericarditis. Internal and Emergency Medicine, 2019, 14, 745-751.	2.0	21
45	FR10444â€¦EFFICACY AND SAFETY OF SECUKINUMAB IN PATIENTS WITH PSORIATIC ARTHRITIS FOLLOWING INADEQUATE RESPONSE TO SYNTHETIC OR BIOLOGICAL DISEASE MODIFYING ANTIRHEUMATIC DRUGS IN REAL-LIFE SETTINGS. , 2019, , .		0
46	AB0375â€¦HYPOGAMMAGLOBULINEMIA AFTER RITUXIMAB TREATMENT IN PATIENTS WITH RHEUMATOID ARTHRITIS IS NOT RARE AND IS ASSOCIATED WITH BETTER RESPONSE. , 2019, , .		0
47	Predictors of switching from nonsteroidal anti-inflammatory drugs to corticosteroids in patients with acute pericarditis and impact on clinical outcome. Hellenic Journal of Cardiology, 2019, 60, 357-363.	1.0	10
48	<i>Pneumocystis Jirovecii</i> Pneumonia after Initiation of Tofacitinib Therapy in Rheumatoid Arthritis: Case-Based Review. Mediterranean Journal of Rheumatology, 2019, 30, 167.	0.8	6
49	Development of an ANCA-Associated Vasculitides Patient Registry in Greece. Mediterranean Journal of Rheumatology, 2019, 31, 84.	0.8	3
50	Twenty Years of Targeted Treatment in Rheumatoid Arthritis in the Greek Databases: Achievements and Unmet Needs. Mediterranean Journal of Rheumatology, 2019, 30, 141.	0.8	1
51	2018 Position Paper on Biosimilars of the Greek Rheumatology Society and Professional Association of Greek Rheumatologists. Mediterranean Journal of Rheumatology, 2019, 30, 82.	0.8	1
52	Low disease activityâ€”irrespective of serologic status at baselineâ€”associated with reduction of corticosteroid dose and number of flares in patients with systemic lupus erythematosus treated with belimumab: A real-life observational study. Seminars in Arthritis and Rheumatism, 2018, 48, 467-474.	3.4	59
53	Severe pancytopenia and splenomegaly associated with felty's syndrome, both fully responsive solely to corticosteroids. Clinical Case Reports (discontinued), 2018, 6, 509-512.	0.5	2
54	Recurrent ventricular arrhythmia in a patient with aortitis and myocardial inflammation due to possible immunoglobulin G4â€”related disease. Internal Medicine Journal, 2018, 48, 598-601.	0.8	1

#	ARTICLE	IF	CITATIONS
55	The effect of TNF- α antagonists on aortic stiffness and wave reflections: a meta-analysis. <i>Clinical Rheumatology</i> , 2018, 37, 515-526.	2.2	59
56	Prevalence of comorbidities in systemic sclerosis versus rheumatoid arthritis: a comparative, multicenter, matched-cohort study. <i>Arthritis Research and Therapy</i> , 2018, 20, 267.	3.5	24
57	Individual Drugs in Rheumatology and the Risk of Infection. , 2018, , 445-464.		0
58	The Role of Colchicine in Pericardial Syndromes. <i>Current Pharmaceutical Design</i> , 2018, 24, 702-709.	1.9	20
59	Multicenter Cross-sectional Study of Patients with Rheumatoid Arthritis in Greece: Results from a cohort of 2.491 patients. <i>Mediterranean Journal of Rheumatology</i> , 2018, 29, 27-37.	0.8	13
60	Five-year prospective multi-center cohort study of patients with giant cell arteritis in Greece. <i>Mediterranean Journal of Rheumatology</i> , 2018, 29, 103-105.	0.8	2
61	Rheumatoid Arthritis-associated Interstitial Lung Disease in Greece: A Multicentre Epidemiological and Clinical Study. <i>Mediterranean Journal of Rheumatology</i> , 2018, 29, 236-239.	0.8	1
62	High 3-year golimumab survival in patients with rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis: real world data from 328 patients. <i>Clinical and Experimental Rheumatology</i> , 2018, 36, 254-262.	0.8	17
63	Combined brain and heart magnetic resonance imaging in systemic vasculitides: fiction or real need?. <i>Clinical and Experimental Rheumatology</i> , 2018, 36 Suppl 111, 152-159.	0.8	4
64	Infections and vasculitis. <i>Current Opinion in Rheumatology</i> , 2017, 29, 17-23.	4.3	18
65	Regulatory t cells restrain autophagy in dendritic cells to ameliorate autoimmunity in a ctla4 dependent fashion. , 2017, , .		0
66	Hepatitis B Reactivation in Rheumatic Diseases. <i>Rheumatic Disease Clinics of North America</i> , 2017, 43, 133-149.	1.9	34
67	The Therapeutic Role of Interleukin-1 Inhibition in Idiopathic Recurrent Pericarditis: Current Evidence and Future Challenges. <i>Frontiers in Medicine</i> , 2017, 4, 78.	2.6	38
68	Increased Frequency of Peripheral B and T Cells Expressing Granulocyte Monocyte Colony-Stimulating Factor in Rheumatoid Arthritis Patients. <i>Frontiers in Immunology</i> , 2017, 8, 1967.	4.8	8
69	Tregs restrain dendritic cell autophagy to ameliorate autoimmunity. <i>Journal of Clinical Investigation</i> , 2017, 127, 2789-2804.	8.2	92
70	Study of the natural course and specific immunity after herpes zoster in patients with rheumatoid arthritis receiving biologic DMARDs. <i>Mediterranean Journal of Rheumatology</i> , 2017, 28, 164-168.	0.8	1
71	Biologic treatment for rheumatic disease: real-world big data analysis from the Greek country-wide prescription database. <i>Clinical and Experimental Rheumatology</i> , 2017, 35, 579-585.	0.8	14
72	Anakinra. <i>Journal of Cardiovascular Medicine</i> , 2016, 17, 256-262.	1.5	54

#	ARTICLE	IF	CITATIONS
73	Clinical and financial burden of active lupus in Greece: a nationwide study. <i>Lupus</i> , 2016, 25, 1385-1394.	1.6	22
74	Nailfold Videocapillaroscopic Features and Other Clinical Risk Factors for Digital Ulcers in Systemic Sclerosis: A Multicenter, Prospective Cohort Study. <i>Arthritis and Rheumatology</i> , 2016, 68, 2527-2539.	5.6	122
75	Immunization in patients with inflammatory rheumatic diseases. <i>Best Practice and Research in Clinical Rheumatology</i> , 2016, 30, 946-963.	3.3	13
76	Prevention of HBV reactivation in patients treated with biologic agents. <i>Expert Review of Clinical Pharmacology</i> , 2016, 9, 579-589.	3.1	11
77	Evaluation of liver fibrosis by transient elastography (FibroScan®) in rheumatic patients during methotrexate treatment. <i>Mediterranean Journal of Rheumatology</i> , 2016, 27, 40-47.	0.8	2
78	54-year-old woman with aortic dissection and paraparesis due to aortitis. <i>Mediterranean Journal of Rheumatology</i> , 2016, 27, 29-30.	0.8	0
79	Safety profile of repeated rituximab cycles in unselected rheumatoid arthritis patients: a long-term, prospective real-life study. <i>Clinical and Experimental Rheumatology</i> , 2016, 34, 893-900.	0.8	28
80	Vasculitides and Hepatitis C Infection. , 2015, , 773-791.		0
81	HCV Treatments and Their Integration Into Rheumatology. <i>Current Rheumatology Reports</i> , 2015, 17, 51.	4.7	2
82	Rituximab for eosinophilic granulomatosis with polyangiitis with severe vasculitic neuropathy: Case report and review of current clinical evidence. <i>Seminars in Arthritis and Rheumatism</i> , 2015, 45, 60-66.	3.4	24
83	Frequent conversion of tuberculosis screening tests during anti-tumour necrosis factor therapy in patients with rheumatic diseases. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 1848-1853.	0.9	46
84	Adalimumab decreases aortic stiffness independently of its effect in disease activity in patients with rheumatoid arthritis. <i>Clinical Rheumatology</i> , 2015, 34, 359-364.	2.2	24
85	Rheumatologic aspects of viral infections. , 2015, , 912-917.		1
86	Hepatitis B reactivation following treatment with abatacept in a patient with past hepatitis B virus infection. <i>Rheumatology</i> , 2014, 53, 195-196.	1.9	29
87	Interleukin-8 as a predictor of acute idiopathic pericarditis recurrences. A pilot study. <i>International Journal of Cardiology</i> , 2014, 172, e463-e464.	1.7	12
88	Anakinra for the management of resistant idiopathic recurrent pericarditis. Initial experience in 10 adult cases: Table A1. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 2215-2217.	0.9	68
89	Tissue factor expression in neutrophil extracellular traps and neutrophil derived microparticles in antineutrophil cytoplasmic antibody associated vasculitis may promote thromboinflammation and the thrombophilic state associated with the disease. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 1854-1863.	0.9	229
90	Can Nucleos(t)ide Analogue (NA) Therapy Ever be Stopped in HBeAg-Negative Chronic Hepatitis B?. <i>Current Hepatology Reports</i> , 2014, 13, 256-263.	0.9	4

#	ARTICLE	IF	CITATIONS
91	The Natural Course of Chronic Hepatitis B Virus Infection and Its Management. <i>Advances in Pharmacology</i> , 2013, 67, 247-291.	2.0	21
92	Viral Hepatitis: Review of Arthritic Complications and Therapy for Arthritis in the Presence of Active HBV/HCV. <i>Current Rheumatology Reports</i> , 2013, 15, 319.	4.7	10
93	Long-term safety of rituximab in patients with rheumatic diseases and chronic or resolved hepatitis B virus infection. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 308-310.	0.9	48
94	Hepatitis C Virus (HCV)-Related Cryoglobulinemia: Cryoglobulin Type and Anti-HCV Profile. <i>Vaccine Journal</i> , 2013, 20, 698-703.	3.1	19
95	The safety of anti-TNF therapy in patients with hepatitis B and C virus infection. <i>International Journal of Clinical Rheumatology</i> , 2012, 7, 191-196.	0.3	1
96	Successful treatment of adult patients with idiopathic recurrent pericarditis with an interleukin-1 receptor antagonist (anakinra). <i>International Journal of Cardiology</i> , 2012, 160, 66-68.	1.7	54
97	Sustained Responses and Loss of HBsAg in HBeAg-Negative Patients With Chronic Hepatitis B Who Stop Long-Term Treatment With Adefovir. <i>Gastroenterology</i> , 2012, 143, 629-636.e1.	1.3	286
98	Management of rheumatic disease with comorbid HBV or HCV infection. <i>Nature Reviews Rheumatology</i> , 2012, 8, 348-357.	8.0	67
99	What Should Be the Endpoints of Oral Therapy in HBeAg-positive Versus HBeAg-negative Patients with Chronic Hepatitis B. <i>Current Hepatitis Reports</i> , 2012, 11, 65-69.	0.3	1
100	Should we routinely treat patients with autoimmune/rheumatic diseases and chronic hepatitis B virus infection starting biologic therapies with antiviral agents? Yes. <i>European Journal of Internal Medicine</i> , 2011, 22, 572-575.	2.2	20
101	Fatal hepatitis B virus reactivation due to a lamivudine mutant despite undetectable initial viral load. <i>European Journal of Gastroenterology and Hepatology</i> , 2011, 23, 109.	1.6	3
102	Is There a Place for Cardiovascular Magnetic Resonance Imaging in the Evaluation of Cardiovascular Involvement in Rheumatic Diseases?. <i>Seminars in Arthritis and Rheumatism</i> , 2011, 41, 488-496.	3.4	28
103	High levels of HCV core+1 antibodies in HCV patients with hepatocellular carcinoma. <i>Journal of General Virology</i> , 2011, 92, 1343-1351.	2.9	29
104	Comparison of Two Gamma Interferon Release Assays and Tuberculin Skin Testing for Tuberculosis Screening in a Cohort of Patients with Rheumatic Diseases Starting Anti-Tumor Necrosis Factor Therapy. <i>Vaccine Journal</i> , 2011, 18, 2102-2108.	3.1	57
105	The Complex Management of Viral-Related Autoimmune Diseases. , 2011, , 345-357.		0
106	Rheumatic manifestations of hepatitis. <i>Current Opinion in Rheumatology</i> , 2010, 22, 91-96.	4.3	18
107	Subacute Thyroiditis Presenting as Fever of Unknown Origin in a Patient With Rheumatoid Arthritis Under Etanercept Treatment. <i>Journal of Clinical Rheumatology</i> , 2010, 16, 88-89.	0.9	14
108	Long-term safety of anti-TNF treatment in patients with rheumatic diseases and chronic or resolved hepatitis B virus infection. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 1352-1355.	0.9	133

#	ARTICLE	IF	CITATIONS
109	Prevalence of interatrial block in patients with Friedreich's Ataxia. <i>International Journal of Cardiology</i> , 2010, 145, 386-387.	1.7	10
110	ECG Changes Mimicking Myocardial Infarction. <i>American Journal of Medicine</i> , 2010, 123, 996-998.	1.5	1
111	Preventive influenza vaccination for patients with rheumatoid arthritis. A need for an international campaign. <i>Clinical Rheumatology</i> , 2009, 28, 103-104.	2.2	7
112	Current treatment options for HBV infection. <i>Current Hepatitis Reports</i> , 2009, 8, 26-30.	0.3	1
113	Quantitative HBsAg titer as predictor of response to therapy. <i>Current Hepatitis Reports</i> , 2009, 8, 169-172.	0.3	2
114	Cryoglobulinemia. , 2009, , 269-273.		0
115	Acute splenic sequestration crisis (ASSC) in an adult patient with β^2 -thalassemia sickle cell disease: a life-threatening complication. <i>Annals of Hematology</i> , 2008, 87, 499-500.	1.8	2
116	Sensorineural hearing loss complicating severe rickettsial diseases: Report of two cases. <i>Journal of Infection</i> , 2008, 56, 74-76.	3.3	23
117	Cellular immune responses in hepatitis B virus e antigen negative chronic hepatitis B. <i>Journal of Viral Hepatitis</i> , 2008, 15, 817-826.	2.0	10
118	Virally associated arthritis 2008: clinical, epidemiologic, and pathophysiologic considerations. <i>Arthritis Research and Therapy</i> , 2008, 10, 215.	3.5	76
119	Unusual combination of paraneoplastic manifestations in a patient with metastatic gastrointestinal stromal tumor (GIST). <i>Scandinavian Journal of Gastroenterology</i> , 2008, 43, 1012-1015.	1.5	9
120	Severe rhabdomyolysis with hypoglycemia in an adult patient with carnitine palmitoyltransferase II deficiency. <i>European Journal of Internal Medicine</i> , 2008, 19, 289-291.	2.2	10
121	Performance Characteristics of Microparticle Enzyme and Chemiluminescence Immunoassays for Measurement of Anti-HBc Immunoglobulin M in Sera of Patients with HBeAg-Negative Chronic Hepatitis B Virus Infection. <i>Vaccine Journal</i> , 2008, 15, 385-387.	3.1	1
122	Telbivudine in the treatment of chronic hepatitis B. <i>Expert Review of Gastroenterology and Hepatology</i> , 2008, 2, 13-22.	3.0	4
123	Infectious arthritis and immune dysfunction. <i>Current Opinion in Rheumatology</i> , 2008, 20, 442.	4.3	1
124	Usefulness of enzyme-linked immunospot assay (Elispot) compared to tuberculin skin testing for latent tuberculosis screening in rheumatic patients scheduled for anti-tumor necrosis factor treatment. <i>Journal of Rheumatology</i> , 2008, 35, 1271-6.	2.0	42
125	Usefulness of enzyme-linked immunosorbent assay (Elispot) compared to tuberculin skin testing for latent tuberculosis screening in rheumatic patients scheduled for anti-tumor necrosis factor treatment. Addendum. <i>Journal of Rheumatology</i> , 2008, 35, 1464.	2.0	22
126	Thrombotic thrombocytopenic purpura with fatal outcome in a patient with chronic hepatitis C treated with pegylated interferon- α /2b. <i>Scandinavian Journal of Gastroenterology</i> , 2007, 42, 408-409.	1.5	17

#	ARTICLE	IF	CITATIONS
127	First appearance of Crohn's disease following infliximab treatment for spondylarthropathy. Scandinavian Journal of Gastroenterology, 2007, 42, 784-785.	1.5	7
128	Cytochrome P450 enzyme polymorphisms and treatment-related ovarian toxicity in patients with SLE. Nature Clinical Practice Rheumatology, 2007, 3, 492-493.	3.2	0
129	Risks of immunosuppressive therapies including biologic agents in patients with rheumatic diseases and co-existing chronic viral infections. Current Opinion in Rheumatology, 2007, 19, 619-625.	4.3	57
130	Myelodysplastic syndrome presenting as acquired ichthyosis. European Journal of Internal Medicine, 2006, 17, 368-369.	2.2	10
131	Dialogue between the Brain and the Immune System in Inflammatory Arthritis. Annals of the New York Academy of Sciences, 2006, 1088, 132-138.	3.8	12
132	Hepatitis B virus (HBV) reactivation with immunosuppressive therapy in rheumatic diseases: assessment and preventive strategies. Annals of the Rheumatic Diseases, 2006, 65, 983-989.	0.9	195
133	Angioimmunoblastic T-Cell Lymphoma-Associated Arthritis. Journal of Clinical Rheumatology, 2005, 11, 326-328.	0.9	19
134	Extrahepatic immunological complications of hepatitis C virus infection. Aids, 2005, 19, S123-S127.	2.2	29
135	Hashimoto Encephalopathy with Pegylated Interferon Alfa-2b and Ribavirin. Annals of Pharmacotherapy, 2005, 39, 1745-1748.	1.9	20
136	Poststreptococcal reactive arthritis with thoracic spine involvement in an adult. Journal of Rheumatology, 2005, 32, 2002-5.	2.0	3
137	Effect of helicobacter pylori infection on the risk of upper gastrointestinal bleeding in users of nonsteroidal anti-inflammatory drugs. American Journal of Medicine, 2004, 116, 601-605.	1.5	24
138	Hepatitis C Infection and Vasculitis. , 2004, , 189-200.		1
139	Rheumatic manifestations of hepatitis C infection. Current Rheumatology Reports, 2003, 5, 200-204.	4.7	38
140	Hepatitis C virus infection and vasculitis: Implications of antiviral and immunosuppressive therapies. Arthritis and Rheumatism, 2002, 46, 585-597.	6.7	100
141	Hepatitis B e antigenâ€“negative chronic hepatitis B. Hepatology, 2001, 34, 617-624.	7.3	462
142	Immunopathogenesis of hepatitis B e antigen negative chronic hepatitis B infection. Antiviral Research, 2001, 52, 91-98.	4.1	45
143	Watermelon stomach and familial Mediterranean fever. American Journal of Gastroenterology, 2001, 96, 2512-2513.	0.4	5
144	Complex management issues: management of HCV in the atypical patient. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2000, 14, 277-291.	2.4	6

#	ARTICLE	IF	CITATIONS
145	SELECTED DRUG COMPLICATIONS AND TREATMENT CONFLICTS IN THE PRESENCE OF COEXISTENT DISEASES. Rheumatic Disease Clinics of North America, 1999, 25, 745-777.	1.9	6
146	Rheumatologic manifestations of HIV-I and HTLV-I infections. Cleveland Clinic Journal of Medicine, 1998, 65, 436-441.	1.3	5
147	Musculoskeletal Infections in Patients with Human Immunodeficiency Virus Infection. Medicine (United States), 1997, 76, 284-294.	1.0	107
148	Gammalinolenic Acid and Dihomogammalinolenic Acid Suppress the CD3-Mediated Signal Transduction Pathway in Human T Cells. Clinical Immunology and Immunopathology, 1997, 83, 237-244.	2.0	28
149	Modulation of Human T-Lymphocyte Plasma Membrane Ca +2 Permeability by Imidazole Antimycotics. Immunopharmacology and Immunotoxicology, 1996, 18, 237-245.	2.4	9
150	Defective CD3-Mediated Cell Death in Activated T Cells from Patients with Systemic Lupus Erythematosus: Role of Decreased Intracellular TNF- α . Clinical Immunology and Immunopathology, 1996, 81, 293-302.	2.0	102
151	Effects of an aminosteroid inhibitor of phospholipase C-dependent processes on the TCR-mediated signal transduction pathway in human T cells. Clinical Immunology and Immunopathology, 1995, 77, 59-68.	2.0	11
152	Chronic Hepatitis B and D. , 0, , 26-38.		4